Antibody-drug Conjugates: 'Magic Bullets' Become Reality
Whitepaper
Clinical
ADCs consist of three components: an antibody, a linker, and a payload. An antibody against a tumor antigen acts as a targeted delivery system, guiding the ADC directly towards antigen-expressing tumor cells, avoiding toxicity to healthy cells and unwanted side effects.
About the authors
Jon Stephens
Associate Director & Taxonomist, Pharmaprojects
Jonathan Stephens is Associate Director for Pharmaprojects,
managing a team of drug analysts and overseeing scientific
data enhancements and taxonomy projects. In addition to
collaborating with product development, he also serves Citeline
clients in drug-related Ask the Analyst service, providing insight
into optimal search strategies and drug development landscapes
to address their strategic business needs. Jonathan has been
with Pharmaprojects since 2007 and has bachelor’s and master’s
of philosophy degrees in pharmacology from University of
Portsmouth.
Arbesa Bela
Drug Analyst II, Pharmaprojects
Arbesa Bela is a Drug Analyst II for Pharmaprojects, involved in
various data enhancement projects and supporting the Ask the
Analyst Service. She engages in drug landscape analyses and
expert subject matter queries in the cardiometabolic, infectious,
and genitourinary disease space. Arbesa joined Pharmaprojects
in 2023 and has a degree in bioprocessing of new medicines from
University College London.
